
|Articles|July 1, 2003
Overview of Efalizumab Patient-reported Outcomes Trials
After treatment with the new biologic agents, patient-reported outcomes measuring quality of life were evaluated, since psoriasis has been shown to have a significantly negative impact on patients' physical, psychological, and social functioning.22 Because the condition can affect the ability to perform normal work activities and often causes absence from work, psoriasis can negatively affect a person's job and income.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














